Latest Content

  • Do HCV DAAs Increase HCC Recurrence Risk or Not?

    Paul Y. Kwo MD - 5/25/2017 7 comments / Last Comment: 6/27/2017
    Here’s my take on new data from EASL 2017.
  • EASL 2017: Emerging Therapies for Genotype 3 HCV

    Nancy Reau MD, FAASLD, AGAF - 5/12/2017 6 comments / Last Comment: 6/23/2017
    Genotype 3 HCV infection is concerning, not just because of its natural history but also because of its potential role in reinfection. New data from EASL offer promise for the treatment of this challenging patient population.